Want to create an interactive transcript for this episode?
Podcast: iForumRx.org
Episode: Semaglutide for CKD – Does the FLOW trial impact the standard of care?
Description: Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are one of the established treatments used to slow the progression of CKD and improve outcomes. Â Could perhaps the glucagon-like peptide 1 (GLP-1) receptor agonists provide similar, additive, or different benefits in patients with CKD?Â
Guest Author: John Swegle, PharmD, BCPS, BCACPÂ
Music by Good Talk